The briefing
Biogen said its experimental Alzheimer’s treatment showed signals of reducing tau and slowing cognitive decline, with the lowest dose appearing most promising. The company is moving the therapy into a late-stage trial to further evaluate efficacy and safety.
Original headline
Biogen Alzheimer's drug moves to late stage trial